BridgeBio launches secondary offering of 5,000,000 shares by KKR Genetic Disorder LP
Reuters2026/08/13 21:43- BridgeBio launched a secondary public offering of 5,000,000 common shares sold by KKR Genetic Disorder L.P.
- No shares are being sold by BridgeBio; no proceeds will go to the company.
- William Blair, Goldman Sachs, KKR to act as joint book-running managers; deal terms depend on market conditions.
- Shares will be offered under BridgeBio’s Form S-3ASR automatic shelf registration statement, effective July 24, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
